Joint Symptoms, Aromatase Inhibitor-Related Adverse Reactions, Are Indirectly Associated with Decreased Serum Estradiol
Table 3
Clinical parameters of patients with hot flashes and without hot flashes ().
With joint Symptoms
Without joint symptoms
P value of chi square tests
Univariate Analysisa
Multivariate Analysisa
Odds ratio (95% CI)
P value
Odds ratio (95% CI)
P value
Age (years)
<55 55–65 65≤
4 11 4
4 42 39
0.33 (0.14–0.78)
<.05
0.81 (0.18–3.63)
NS
Age at menarche (years)
<12 12–15 15≤
3 15 1
2 72 11
0.21 (0.05–0.95)
<.05
0.48 (0.07–3.27)
NS
No. of childbirths
None 1-2 2≤
2 12 5
8 59 18
1.14 (0.46–2.83)
NS
BMI (kg/m2)
<25 25–30 30≤
8 10 1
54 24 7
1.53 (0.73–3.21)
NS
Therapy prior to AI administration
None Yes
7 12
59 26
Not analyzedb
Time from menopausec (years)
<5 5–10 10≤
7 8 4
9 24 52
0.31 (0.16–0.63)
<.01
0.42 (0.13–1.37)
NS
Pre-AI administration %YAM (%)
<70 70–80 80≤
1 8 8
30 34 17
2.98 (1.35–6.59)
<.01
2.63 (0.99–7.01)
.053
Pre-AI administration %AGE (%)
<80 80–100 100≤
2 6 9
12 36 33
1.38 (1.35–3.03)
NS
Change of E2
Rebound Decreased
1 18
7 78
1.62 (0.19–13.9)
NS
Change of T-chold
Elevated Non-elevated
10 6
21 56
0.31 (0.11–0.88)
<.05
0.43 (0.13–1.43)
NS
Change of %AGEd
Not -decreased Decreased
10 7
51 28
1.36 (0.50–3.73)
NS
BMI: body mass index; AI: aromatase inhibitor; %YAM: % young adult mean value; %AGE: % age-matched mean value; E2: estradiol; T-chol: total cholesterol; NS: not significance. aMaltivariate logistic regression analysis (trend analysis). bBecause of the diversity of the treatment methods employed, statistical analyses were not performed. cTime from menopause until AI administration. dExcluded patients with medicine.
